“Global Next-Generation Antibody Therapies market set to grow to $17bn by 2023” says new Visiongain report

25 September 2018
Pharma

Visiongain has launched a new pharma report: Global Next-Generation Antibody Therapies Market Forecast 2018-2028: Antibody-Drug Conjugates, Engineered Antibodies, Bispecific Antibodies, Antibody Fragments & ALPs, Biosimilar Antibodies.

Next-generation antibody therapies are becoming established treatments for haematological malignancies and solid tumours (phase 3) pipelines are relatively sparse, however, with most pipeline candidates in phase 1 or phase 2 of development. Growth will be rapid from the middle of the forecast period as new therapies are approved. New therapies will likely compete with currently marketed monoclonal antibodies, biosimilars, and novel small molecule drugs. Increasing collaboration between biotechnology and big pharma companies will drive pipeline development, which may result in the dominance of a small number of technology platforms, as seen for example in the market for antibody-drug conjugates.

The lead analyst of the report commented "Success for developers of next-generation antibody therapies will depend on a number of factors, including having a technology platform that offers some advantage over standard monoclonal antibodies, the ability to advance a novel therapy through proof of concept, and partnership opportunities with Big Pharma.

Products that offer superior or additional efficacy compared to currently available therapies will be needed in order to compete against existing therapies and the biosimilars that are expected to become available for these therapies in developed markets. Alternatively, targeting new indications and new antigens will expand the potential in the market."

Leading companies featured in the report include Amgen, Inc., GlaxoSmithKline (GSK), Kirin Holdings (Kyowa Hakko Kirin Co., Ltd.), Merck KGaA, Novartis AG, Pfizer, Inc., Roche, Sanofi, Seattle Genetics, Inc., Shire plc

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Global Asthma & COPD Therapies market set to grow to $46bn by 2024” says new Visiongain report

ecent studies and expert opinion suggest that the asthma and COPD market is more segregated than previously believed.

19 March 2019

Read

“Global Anaesthesia Drugs market set to grow to $11.8bn by 2024” says new Visiongain report

The intravenous route is the most commonly used route of administration owing to its high effectiveness during critical surgeries, its high adoption in hospitals, and availability of advanced intravenous drugs which cater the need of surgeons.

19 March 2019

Read

“The Global Pharma Contract Sales market will be driven by cost saving and the need for more flexibility” says new Visiongain report

With higher-cost therapies in development, combined with increasing burdens on healthcare budgets from ageing populations and rising disease incidence, market access is becoming more challenging in countries worldwide.

28 February 2019

Read

“Drug Delivery Technologies market set to grow to $355bn by 2024” says new Visiongain report

The potential use of drug delivery technologies in product lifecycle management and the enhancement of drug efficacy in many therapeutic sectors will act as drivers for growth of the market over the coming decade.

28 February 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever
WOOCS 2.2.1